Glycans or carbohydrates are one of the fundamental class of macromolecules present in biological systems and are formed of individual sugar units called monosaccharides linked to each other in multiple ways. Glycans are involved in every aspects of biochemistry of life. Glycoscience thus refers to the discipline of life science that deals with the study of synthesis, structural elucidation, functional property identification, mechanism of interaction of glycans with biological molecules such as lipids and proteins.
The global glycobiology market is estimated to account for US$ 1,007.4 Mn in terms of value in 2020 and is expected to reach US$ 2,397.5 Mn by the end of 2027.
Global Glycobiology Market: Drivers
Increasing prevalence of contagious diseases is expected to boost growth of the global glycobiology market over the forecast period. For instance, around 1 million adults in the U.S. suffer from pneumonia, annually and the disease results in 50,000 deaths, annually.
Global Glycobiology Market: Opportunities
R&D related to oligosaccharides is expected to offer lucrative growth opportunities for players in the global glycobiology market. For instance, in February 2020, researchers from University of Kentucky, U.S., reported the use of a high-throughput assay to determine the effect of various post-translational modifications of the Chondroitin sulfate proteoglycansaggrecan upon neurite outgrowth from NS-1 cells.
Global Glycobiology Market: Restraints
Heterogeneity in glycan forms challenges determination of proper structure of the associated protein. This could result in application of several different analytical techniques – largely not understandable by a large section of the academic population, thereby limiting use of the proteins and associated techniques in research institutes working a smaller scale. Such scenario is expected to hamper growth of the market.
Moreover, lack of trained professionals to perform various protocols in glycobiology research is also expected to limit growth of the market.
Enzymes segment in the global glycobiology market was valued at US$ 487.1 Mn in 2019 and is expected to reach US$ 1,371.0 Mn by 2027 at a CAGR of 13.6% during the forecast period. Enzymes are necessary products to carry out glycobiology processes and studies in laboratories which is expected to support growth of the segment over the forecast period.
The Galactosidase segment held dominant position in the global glycobiology market in 2019, accounting for 27.2% share in terms of value, followed by GlcNAc Transferases and Carbohydrate Kinases, respectively. Galactosidases are required for hydrolysis of β-galactosides into monosaccharides which is a critical step for study of glycobiology.
The drug discovery and development segment held dominant position in the global glycobiology market in 2019, accounting for 53.9% share in terms of value. Carbohydrate based drug discovery and development is increasingly being conducted due to advances in analysis and synthesis of carbohydrates which is expected to support growth of the segment.
Glycosylation is the most common post-translational modification in eukaryotic proteins and is proving an important tool for development of protein-based drugs. Academia and industries in Europe are increasingly investing on innovative techniques in glycoscience in a vast field of medicine including drug delivery systems, anti-inflammatory therapeutics, virology & immunology applications with special focus on oncology and HIV.
In Europe, several non-profit and governmental organizations are providing research grants to academia and research institutes in order to promote glycoscience research. For instance, the National Research, Development and Innovation Office of Hungary and the European Regional Development Fund funded a research of University of Debrecen that, in February 2020, reported synthesis of new series of 2-c-(β-d-glucopyranosyl)-pyrimidines and their evaluation as inhibitors of some glycoenzymes.
Global Glycobiology Market: Competitive Landscape
Major players operating in the global glycobiology market include, Merck KGaA, Bio-Techne Corporation, Bruker Corporation, Thermo Fisher Scientific, Inc., Shimadzu Corporation, Plexera Bioscience LLC, New England Biolabs Inc., Agilent Technologies, Inc., and ProZyme, Inc.
Global Glycobiology Market: Key Developments
January 2020: InterVenn Biosciences, a U.S.-based biotechnology company, announced multiple achievements in its development of AI-enabled glycoproteomics, which include positive interim results from its first clinical trial that assessed a new, simple blood test for the care of patients with ovarian tumors
October 2018: GO Therapeutics, Inc., a developer of antibody-based cancer therapeutics, entered into a license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to grant Hoffmann-La Roche Inc. a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target to develop and commercialize a new glycotargeting bispecific antibody